Does the media refer more to RXRX or BNTC?

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Recursion Pharmaceuticals' score of 0.86 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SNDX or BNTC?

In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Syndax Pharmaceuticals and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Syndax Pharmaceuticals' score of 1.65 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BNTC or ANAB?

In the previous week, AnaptysBio had 10 more articles in the media than Benitec Biopharma. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat AnaptysBio's score of 1.15 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AnaptysBio 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or BNTC?

In the previous week, Vir Biotechnology had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Vir Biotechnology and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Vir Biotechnology's score of 1.30 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MAZE or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Benitec Biopharma N/A -34.82% -34.11%

Does the media prefer MAZE or BNTC?

In the previous week, Maze Therapeutics had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Maze Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Maze Therapeutics' score of 1.42 indicating that Benitec Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Benitec Biopharma (BNTC) Competitors

$12.47 -0.20 (-1.58%)

As of 08/28/2026 04:00 PM Eastern

Compare

BNTC vs. RXRX, SNDX, ANAB, VIR, and MAZE

Should you buy Benitec Biopharma stock or one of its competitors? Benitec Biopharma's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), Syndax Pharmaceuticals (SNDX), AnaptysBio (ANAB), Vir Biotechnology (VIR), and Maze Therapeutics (MAZE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Benitec Biopharma compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Recursion Pharmaceuticals currently has a consensus target price of $8.06, suggesting a potential upside of 141.32%. Benitec Biopharma has a consensus target price of $24.80, suggesting a potential upside of 98.88%. Given Recursion Pharmaceuticals' higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Recursion Pharmaceuticals and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Recursion Pharmaceuticals' score of 0.86 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Benitec Biopharma has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Benitec Biopharma's return on equity of -34.82% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Benitec Biopharma	N/A	-34.82%	-34.11%

Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Benitec Biopharma has lower revenue, but higher earnings than Recursion Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	23.94	-$644.76M	-$1.04	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

Recursion Pharmaceuticals beats Benitec Biopharma on 8 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

52.2% of Benitec Biopharma shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Syndax Pharmaceuticals presently has a consensus target price of $41.55, indicating a potential upside of 112.62%. Benitec Biopharma has a consensus target price of $24.80, indicating a potential upside of 98.88%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma has lower revenue, but higher earnings than Syndax Pharmaceuticals. Benitec Biopharma is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.05	-$285.42M	-$2.51	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Syndax Pharmaceuticals and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Syndax Pharmaceuticals' score of 1.65 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Benitec Biopharma has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Benitec Biopharma's return on equity of -34.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Benitec Biopharma	N/A	-34.82%	-34.11%

Syndax Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Syndax Pharmaceuticals and Benitec Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Benitec Biopharma compare to AnaptysBio?

Benitec Biopharma (NASDAQ:BNTC) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Benitec Biopharma has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
AnaptysBio	-11.53%	N/A	-7.75%

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 31.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AnaptysBio has higher revenue and earnings than Benitec Biopharma. AnaptysBio is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
AnaptysBio	$234.60M	7.10	-$13.23M	-$1.08	N/A

In the previous week, AnaptysBio had 10 more articles in the media than Benitec Biopharma. MarketBeat recorded 12 mentions for AnaptysBio and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat AnaptysBio's score of 1.15 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AnaptysBio	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma currently has a consensus price target of $24.80, suggesting a potential upside of 98.88%. AnaptysBio has a consensus price target of $80.00, suggesting a potential upside of 42.15%. Given Benitec Biopharma's higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Benitec Biopharma has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Summary

AnaptysBio beats Benitec Biopharma on 10 of the 15 factors compared between the two stocks.

How does Benitec Biopharma compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Vir Biotechnology had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 10 mentions for Vir Biotechnology and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Vir Biotechnology's score of 1.30 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vir Biotechnology currently has a consensus price target of $21.57, indicating a potential upside of 99.18%. Benitec Biopharma has a consensus price target of $24.80, indicating a potential upside of 98.88%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Benitec Biopharma	N/A	-34.82%	-34.11%

Vir Biotechnology has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Benitec Biopharma has lower revenue, but higher earnings than Vir Biotechnology. Benitec Biopharma is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$302.59M	6.06	-$437.99M	-$1.86	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

Vir Biotechnology beats Benitec Biopharma on 10 of the 16 factors compared between the two stocks.

How does Benitec Biopharma compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Maze Therapeutics had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Maze Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Maze Therapeutics' score of 1.42 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

52.2% of Benitec Biopharma shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maze Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 140.52%. Benitec Biopharma has a consensus target price of $24.80, indicating a potential upside of 98.88%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Benitec Biopharma's return on equity of -34.82% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Benitec Biopharma	N/A	-34.82%	-34.11%

Maze Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Benitec Biopharma has lower revenue, but higher earnings than Maze Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$20M	76.21	-$131.12M	-$2.52	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

Maze Therapeutics beats Benitec Biopharma on 10 of the 15 factors compared between the two stocks.

Get Benitec Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTC vs. The Competition

Export

Metric	Benitec Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$428.39M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-10.94	11.62	273.16	25.45
Price / Sales	N/A	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.36	16.53	12.98	6.14
Net Income	-$37.92M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-7.49%	-0.31%	0.13%	-0.80%
1 Month Performance	5.14%	9.80%	7.08%	4.13%
1 Year Performance	-5.82%	55.66%	24.67%	15.17%

Benitec Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTC Benitec Biopharma	2.3336 of 5 stars	$12.47 -1.6%	$24.80 +98.9%	-5.8%	$428.39M	N/A	N/A	20	Positive News
RXRX Recursion Pharmaceuticals	1.8819 of 5 stars	$3.56 +9.5%	$8.06 +126.4%	-28.9%	$1.74B	$74.68M	N/A	400	Analyst Upgrade Options Volume
SNDX Syndax Pharmaceuticals	3.1379 of 5 stars	$19.92 +1.8%	$41.55 +108.6%	+19.7%	$1.73B	$172.35M	N/A	110	News Coverage Positive News
ANAB AnaptysBio	3.0144 of 5 stars	$58.37 -0.1%	$80.00 +37.1%	+176.8%	$1.73B	$234.60M	N/A	100	News Coverage Positive News Upcoming Earnings Analyst Downgrade
VIR Vir Biotechnology	2.5592 of 5 stars	$10.71 +8.1%	$20.63 +92.6%	+119.2%	$1.68B	$68.56M	N/A	580	News Coverage Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTC) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Benitec Biopharma (BNTC) Competitors

BNTC vs. RXRX, SNDX, ANAB, VIR, and MAZE

How does Benitec Biopharma compare to Recursion Pharmaceuticals?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Summary

How does Benitec Biopharma compare to Vir Biotechnology?

Summary

How does Benitec Biopharma compare to Maze Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Benitec Biopharma (BNTC) Competitors

BNTC vs. RXRX, SNDX, ANAB, VIR, and MAZE

How does Benitec Biopharma compare to Recursion Pharmaceuticals?

Do analysts recommend RXRX or BNTC?

Do insiders & institutionals have more ownership in RXRX or BNTC?

Does the media refer more to RXRX or BNTC?

Is RXRX or BNTC more profitable?

Which has more risk & volatility, RXRX or BNTC?

Which has better valuation & earnings, RXRX or BNTC?

Summary

How does Benitec Biopharma compare to Syndax Pharmaceuticals?

Do insiders and institutionals believe in SNDX or BNTC?

Do analysts prefer SNDX or BNTC?

Which has preferable valuation and earnings, SNDX or BNTC?

Does the media prefer SNDX or BNTC?

Is SNDX or BNTC more profitable?

Which has more risk & volatility, SNDX or BNTC?

Summary

How does Benitec Biopharma compare to AnaptysBio?

Is BNTC or ANAB more profitable?

Do insiders & institutionals hold more shares of BNTC or ANAB?

Which has better valuation and earnings, BNTC or ANAB?

Does the media favor BNTC or ANAB?

Do analysts rate BNTC or ANAB?

Which has more risk and volatility, BNTC or ANAB?

Summary

How does Benitec Biopharma compare to Vir Biotechnology?

Does the media prefer VIR or BNTC?

Do institutionals & insiders hold more shares of VIR or BNTC?

Do analysts rate VIR or BNTC?

Is VIR or BNTC more profitable?

Which has more volatility & risk, VIR or BNTC?

Which has better earnings and valuation, VIR or BNTC?

Summary

How does Benitec Biopharma compare to Maze Therapeutics?

Does the media prefer MAZE or BNTC?

Do insiders & institutionals hold more shares of MAZE or BNTC?

Do analysts rate MAZE or BNTC?

Is MAZE or BNTC more profitable?

Which has more risk and volatility, MAZE or BNTC?

Which has higher valuation and earnings, MAZE or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTC vs. The Competition

Benitec Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools